Anixa Biosciences Says A Genomic Variant Analysis Indicates That Its Potential Compounds ‘may be even more effective against the Delta variant than the original wild type SARS-CoV-2.’
Anixa Biosciences, Inc. (NASDAQ:ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that a genomic variant analysis indicates that its